articleNature AgingJan 9, 2024HYBRID OA

Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles

BMBetty M. TijmsEMEleonora M. VromenOMOlav MjaavattenHHHenne HolstegeLMLianne M. Reus

Amsterdam Neuroscience · Amsterdam University Medical Centers · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this heterogeneity is critical for AD drug development. Here we define AD molecular subtypes using mass spectrometry proteomics in cerebrospinal fluid, based on 1,058 proteins, with different levels in individuals with AD (n = 419) compared to controls (n = 187). These AD subtypes had alterations in protein levels that were associated with distinct molecular processes: subtype 1 was characterized by proteins related to neuronal hyperplasticity; subtype 2 by innate immune activation; subtype 3 by RNA dysregulation; subtype 4 by choroid plexus dysfunction; and subtype 5 by blood-brain barrier impairment. Each subtype was related to…

Citation impact

190
total citations
FWCI
43.17
Percentile
100%
References
119
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Choroid plexus
  • Cerebrospinal fluid
  • Proteomics
  • TREM2
  • Biology
  • Disease
  • Medicine
  • Pathology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding